These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 11767112)

  • 21. Spray freeze drying to produce a stable Delta(9)-tetrahydrocannabinol containing inulin-based solid dispersion powder suitable for inhalation.
    van Drooge DJ; Hinrichs WL; Dickhoff BH; Elli MN; Visser MR; Zijlstra GS; Frijlink HW
    Eur J Pharm Sci; 2005 Oct; 26(2):231-40. PubMed ID: 16084699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Developments in the formulation and delivery of spray dried vaccines.
    Kanojia G; Have RT; Soema PC; Frijlink H; Amorij JP; Kersten G
    Hum Vaccin Immunother; 2017 Oct; 13(10):2364-2378. PubMed ID: 28925794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of absorption enhancers to enhance the dispersibility of spray-dried powders for pulmonary gene therapy.
    Li HY; Seville PC; Williamson IJ; Birchall JC
    J Gene Med; 2005 Aug; 7(8):1035-43. PubMed ID: 15756712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and testing of particulate formulations for the nasal delivery of antibodies.
    Kaye RS; Purewal TS; Alpar OH
    J Control Release; 2009 Apr; 135(2):127-35. PubMed ID: 19059291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein powders for encapsulation: a comparison of spray-freeze drying and spray drying of darbepoetin alfa.
    Nguyen XC; Herberger JD; Burke PA
    Pharm Res; 2004 Mar; 21(3):507-14. PubMed ID: 15070103
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation.
    Saluja V; Amorij JP; Kapteyn JC; de Boer AH; Frijlink HW; Hinrichs WL
    J Control Release; 2010 Jun; 144(2):127-33. PubMed ID: 20219608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Spray-dried powders improve the controlled release of antifungal tioconazole-loaded polymeric nanocapsules compared to with lyophilized products.
    Ribeiro RF; Motta MH; Härter APG; Flores FC; Beck RCR; Schaffazick SR; de Bona da Silva C
    Mater Sci Eng C Mater Biol Appl; 2016 Feb; 59():875-884. PubMed ID: 26652443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery.
    Martinac A; Filipović-Grcić J; Voinovich D; Perissutti B; Franceschinis E
    Int J Pharm; 2005 Mar; 291(1-2):69-77. PubMed ID: 15707733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients.
    Razavi Rohani SS; Abnous K; Tafaghodi M
    Int J Pharm; 2014 Apr; 465(1-2):464-78. PubMed ID: 24560646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and evaluation of nasal formulations of ketorolac.
    Quadir M; Zia H; Needham TE
    Drug Deliv; 2000; 7(4):223-9. PubMed ID: 11195429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective effect of sodium stearate on the moisture-induced deterioration of hygroscopic spray-dried powders.
    Yu J; Romeo MC; Cavallaro AA; Chan HK
    Int J Pharm; 2018 Apr; 541(1-2):11-18. PubMed ID: 29454904
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of directly compressible powders via co-spray drying.
    Gonnissen Y; Remon JP; Vervaet C
    Eur J Pharm Biopharm; 2007 Aug; 67(1):220-6. PubMed ID: 17317123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of feed counterion addition and cyclone type on aerodynamic behavior of alginic-atenolol microparticles produced by spray drying.
    Ceschan NE; Bucalá V; Ramírez-Rigo MV; Smyth HD
    Eur J Pharm Biopharm; 2016 Dec; 109():72-80. PubMed ID: 27697595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody.
    Abdul-Fattah AM; Truong-Le V; Yee L; Nguyen L; Kalonia DS; Cicerone MT; Pikal MJ
    J Pharm Sci; 2007 Aug; 96(8):1983-2008. PubMed ID: 17286290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Jet-vortex spray freeze drying for the production of inhalable lyophilisate powders.
    Wanning S; Süverkrüp R; Lamprecht A
    Eur J Pharm Sci; 2017 Jan; 96():1-7. PubMed ID: 27593988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of operating and formulation variables on the morphology of spray-dried protein particles.
    Maa YF; Costantino HR; Nguyen PA; Hsu CC
    Pharm Dev Technol; 1997 Aug; 2(3):213-23. PubMed ID: 9552449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-viral dried powders for respiratory gene delivery prepared by cationic and chitosan loaded liposomes.
    Colonna C; Conti B; Genta I; Alpar OH
    Int J Pharm; 2008 Nov; 364(1):108-18. PubMed ID: 18775770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery.
    Pozzoli M; Traini D; Young PM; Sukkar MB; Sonvico F
    Drug Dev Ind Pharm; 2017 Sep; 43(9):1510-1518. PubMed ID: 28425305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with L-leucine.
    Najafabadi AR; Gilani K; Barghi M; Rafiee-Tehrani M
    Int J Pharm; 2004 Nov; 285(1-2):97-108. PubMed ID: 15488683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insoluble powder formulation as an effective nasal drug delivery system.
    Ishikawa F; Murano M; Hiraishi M; Yamaguchi T; Tamai I; Tsuji A
    Pharm Res; 2002 Aug; 19(8):1097-104. PubMed ID: 12240934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.